Immunotherapy is currently popular for the treatment of HCC, and nivolumab (anti PD-1), atezolizumab (anti PD-L1), and tremelimumab (anti CTLA-4) have been proven to be effective in the treatment of HCC and are widely used in clinical practice (36). Here, CD274 is linked to hepatocellular carcinoma.